(Q39334954)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22678912%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

title

HLA-G1 and HLA-G5 active dimers are present in malignant cells and effusions: the influence of the tumor microenvironment (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22678912%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22678912%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

7

Edgardo D Carosella

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22678912%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

9

Catherine Menier

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22678912%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

author name string

Sonia Zilberman

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22678912%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Chantal Schenowitz

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22678912%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Sophie Agaugué

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22678912%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Favier Benoît

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22678912%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Béatrice Riteau

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22678912%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Nathalie Rouas-Freiss

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22678912%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

language of work or name

English

0 references

publication date

1 June 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22678912%20AND%20SRC:MED&resulttype=core&format=json

European Journal of Immunology

4 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22678912%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

volume

42

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22678912%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22678912%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

page(s)

1599-1608

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22678912%20AND%20SRC:MED&resulttype=core&format=json

The role of HLA-G in immunity and hematopoiesis.

4 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141761

Recent advances on the non-classical major histocompatibility complex class I HLA-G molecule

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141761

HLA-G molecules: from maternal-fetal tolerance to tissue acceptance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141761

Erythroblasts secrete the nonclassical HLA-G molecule from primitive to definitive hematopoiesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141761

HLA-G: from biology to clinical benefits

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141761

Expression of tolerogenic HLA-G molecules in cancer prevents antitumor responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141761

A class I antigen, HLA-G, expressed in human trophoblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141761

Direct evidence to support the role of HLA-G in protecting the fetus from maternal uterine natural killer cytolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141761

A novel immunoglobulin superfamily receptor for cellular and viral MHC class I molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141761

A common inhibitory receptor for major histocompatibility complex class I molecules on human lymphoid and myelomonocytic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141761

MICA triggering signal for NK cell tumor lysis is counteracted by HLA-G1-mediated inhibitory signal

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141761

Human inhibitory receptors Ig-like transcript 2 (ILT2) and ILT4 compete with CD8 for MHC class I binding and bind preferentially to HLA-G

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141761

Tolerization of dendritic cells by HLA-G.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141761

Complexes of HLA-G protein on the cell surface are important for leukocyte Ig-like receptor-1 function

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141761

The CD85J/leukocyte inhibitory receptor-1 distinguishes between conformed and beta 2-microglobulin-free HLA-G molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141761

A homodimeric complex of HLA-G on normal trophoblast cells modulates antigen-presenting cells via LILRB1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141761

HLA-G homodimer-induced cytokine secretion through HLA-G receptors on human decidual macrophages and natural killer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141761

Disulfide bond-mediated dimerization of HLA-G on the cell surface.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141761

Crystal structure of HLA-G: a nonclassical MHC class I molecule expressed at the fetal-maternal interface

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141761

HLA-G complexes are observed on the cell surface

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141761

Efficient leukocyte Ig-like receptor signaling and crystal structure of disulfide-linked HLA-G dimer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141761

HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141761

Analysis of HLA antigen expression in benign and malignant melanocytic lesions reveals that upregulation of HLA-G expression correlates with malignant transformation, high inflammatory infiltration and HLA-A1 genotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141761

HLA-G in cancer: a way to turn off the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141761

Switch of HLA-G alternative splicing in a melanoma cell line causes loss of HLA-G1 expression and sensitivity to NK lysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141761

Lack of HLA class I antigen expression by cultured melanoma cells FO-1 due to a defect in B2m gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141761

HLA-G2, -G3, and -G4 isoforms expressed as nonmature cell surface glycoproteins inhibit NK and antigen-specific CTL cytolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141761

Malignant melanoma in the 21st century: the emerging molecular landscape

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141761

The MAPK pathway in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141761

Alloreactive CD4+ and CD8+ T cells express the immunotolerant HLA-G molecule in mixed lymphocyte reactions: in vivo implications in transplanted patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141761

Antigen-processing machinery breakdown and tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141761

beta2-Microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141761

A human histocompatibility leukocyte antigen (HLA)-G-specific receptor expressed on all natural killer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141761

HLA class I molecules regulate IFN-gamma production induced in NK cells by target cells, viral products, or immature dendritic cells through the inhibitory receptor ILT2/CD85j

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141761

ILT2/HLA-G interaction impairs NK-cell functions through the inhibition of the late but not the early events of the NK-cell activating synapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141761

Altered glycosylation in tumours focused to cancer diagnosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141761

Glycosylation changes on serum glycoproteins in ovarian cancer may contribute to disease pathogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141761

Human neuroblastoma cells trigger an immunosuppressive program in monocytes by stimulating soluble HLA-G release

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141761

Modulation of dendritic cell differentiation by HLA-G and ILT4 requires the IL-6--STAT3 signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141761

CD3+CD4low and CD3+CD8low are induced by HLA-G: novel human peripheral blood suppressor T-cell subsets involved in transplant acceptance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141761

Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141761

Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141761

Inhibition of human gamma delta [corrected] T-cell antitumoral activity through HLA-G: implications for immunotherapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141761

HLA-G, -E, -F preworkshop: tools and protocols for analysis of non-classical class I genes transcription and protein expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141761

Characterization of monoclonal antibodies recognizing HLA-G or HLA-E: new tools to analyze the expression of nonclassical HLA class I molecules.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141761

HLA-G turns off erythropoietin receptor signaling through JAK2 and JAK2 V617F dephosphorylation: clinical relevance in polycythemia vera.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141761

Synthesis of beta(2)-microglobulin-free, disulphide-linked HLA-G5 homodimers in human placental villous cytotrophoblast cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141761

inferred from DOI database lookup

7 January 2021

based on heuristic

IL-10 selectively induces HLA-G expression in human trophoblasts and monocytes

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141761

inferred from DOI database lookup

7 January 2021

based on heuristic

HLA-G expression in effusions is a possible marker of tumor susceptibility to chemotherapy in ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141761